This genetic anomaly unites the transcriptional activating domain of SS18 and the transcriptional repressor domains of SSX, giving birth to a fusion product that is supposed to play an important role in the pathogenesis of Synovial Sarcoma, although the exact mechanism still remains unclear. Here, SS18 is linked to synovial sarcoma.